Table 1.

Positive hits from the Cayman Epigenetics Screening Library. These compounds reduced RFP by at least 50% at 24 hpi - the percentage values indicate the RFP levels in cells treated with 1 μM drug relative to vehicle-treated cells (100% RFP) in the screen.

Compound	% RFPa	Mode of action
1) Chaetocinb	10	Methyltransferase inhibitor
2) Apicidinb	12	HDAC inhibitor
3) HC Toxinb	13	HDAC inhibitor
4) Panobinostatb	14	HDAC inhibitor
5) Givinostat	17	HDAC inhibitor
6) Oxamflatin	17	HDAC inhibitor
7) Gemcitabineb	18	DNA synthesis inhibitor
8) Trifluoroacetate salt	29	HDAC inhibitor
9) Pracinostat	20	HDAC inhibitor
10) TSA	22	HDAC inhibitor
11) Lestaurtinib	22	Tyrosine kinase inhibitor
12) Decitabine	25	DNMT-1 inhibitor
12) LAQ824b	32	HDAC inhibitor
14) CAY10603	34	HDAC inhibitor
15) CUDC-101	37	Multi-targeted inhibitor of HDACs, EGFR, HER2
16) M344	41	HDAC inhibitor
17) 4-iodo-SAHA	45	HDAC inhibitor
18) CBHA	47	HDAC inhibitor
19) Scriptaid	49	HDAC inhibitor

^aValues represent the mean of three experimental replicates. The CV for all compounds was <35%, with the exception of CUDC-101 (61%) and LAQ824 (111%).

^bThese compounds were also identified as positive hits when the screen was conducted with all compounds at 0.25 μM. The RFP percentage for chaetocin, apicidin, HC toxin, panobinostat, gemcitabine and LAQ824 were 34%, 42%, 35%, 32%, 44% and 32%, respectively.